Monarch Precision Oncology · 2026 evidence map
Melanoma Precision Oncology Map
Cutaneous, post-PD-1, uveal, acral/mucosal, biomarker, clinical-trial and mechanistic research pathways.
CutaneousUvealAcral / mucosalBRAFKITHLA-A*02:01TIL
Clinical decision support only. Confirm histology, disease stage, resectability, BRAF status, HLA status where relevant, CNS disease, organ function, performance status, prescribing information and local regulatory access before clinical use.